| Literature DB >> 36010070 |
Anna Solé-Ribalta1, Sara Bobillo-Pérez1, Iolanda Jordan-García1.
Abstract
Adrenomedullin has several properties. It acts as a potent vasodilator, has natriuretic effects, and reduces endothelial permeability. It also plays a role in initiating the early hyperdynamic phase of sepsis. Since its discovery, many articles have been published studying the uses and benefits of this biomarker. The aim of this review is to determine the usefulness of adrenomedullin in pediatric patients. Relevant studies covering adrenomedullin in pediatrics (<18 years) and published up until August 2021 were identified through a search of MEDLINE, PubMed, Embase, Web of Science, Scopus, and Cochrane. Seventy studies were included in the present review, most of them with a low level of evidence (IV to VI). Research on adrenomedullin has primarily been related to infection and the cardiovascular field. The performance of adrenomedullin to quantify infection in children seems satisfactory, especially in sepsis. In congenital heart disease, this biomarker seems to be a useful indicator before, during, and after cardiopulmonary bypass. Adrenomedullin seems to be useful in the pediatric population for a large variety of pathologies, especially regarding infection and cardiovascular conditions. However, it should be used in combination with other biomarkers and clinical or analytical variables, rather than as a single tool.Entities:
Keywords: adrenomedullin; biomarker; children; pediatrics
Year: 2022 PMID: 36010070 PMCID: PMC9406574 DOI: 10.3390/children9081181
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Adrenomedullin in critically ill children and in paediatric infections.
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Rey C. et al. (2013) [ | P, O, MC | <18 yr | MR-proADM | To identify biomarkers that can be used as predictors of mortality risk. | PRISM III and PIM mortality risk scores, | 0.866 | 0.79 nmol/L (scores) | 93 | 76 | 33.7/98.2 | MR-proADM appears to improve diagnostic accuracy for detecting patients with higher risk of mortality scores and more than one organ failure. |
|
| |||||||||||
| Jordan I. et al. (2014) [ | P, O, SC | 9 d–13 yr | MR-proADM | To determine | Organ failure, PRISM III, and in-hospital mortality | 0.77 | 2.2 nmol/L | 72.7 | 81 | 31/96.2 | MR-pro-ADM levels are good indicators of disease severity and show better reliability than PCT and CRP for predicting in-hospital mortality. |
| Lan J. et al. (2019) [ | CC, SC | 6–12 yr | PCT | To evaluate the role of MR-proADM and PCT in the early diagnosis of childhood sepsis. | - | 0.869 | 3.46 mmol/L | 85.11 | 71.1 | - | PCT and MR-proADM concentrations significantly increase as severity of sepsis worsens. The diagnostic effect of MR-proADM in children with sepsis was better than that of |
| Solé-Ribalta A. et al. (2020) [ | P, O, SC | <16 yr | PCT | To evaluate the diagnostic, prognostic, and stratification potential of MR-proADM at the onset of fever. | Goldstein 2005 diagnostic criteria | 0.729 | 1.37 nmol/L | 79.4 | 50 | 79.4/50 | PCT appears to be superior to MR-proADM in diagnosing sepsis; MR-proADM in the early stage of sepsis could be a useful tool for the stratification of sepsis and the prediction of morbidity. |
|
| |||||||||||
| Míguez et al. (2016) [ | P, O, SC | 3–16 yr | CRP | To evaluate the usefulness of MR-proADM in diagnosing AA in children presenting with acute abdominal pain. | Histological confirmation on surgeon’s report | 0.75 | 0.34 nmol/L | 93 | 46 | 45/93 | The performance of MR-proADM alone, while statistically significant, is not optimal. MR-proADM levels of <0.35 nmol/L in combination with low CRP seems useful for the identification of children with a low risk of AA. |
| Oikonomopoulou et al. (2019) [ | P, O, MC | <18 yr | MR-proADM CRP WBC and neutrophil count | To investigate the utility of pro-ADM for diagnosing AA. | Histological confirmation on surgeon’s report | 0.66 | 0.35 nmol/L | 92 | 32 | 43/88 | MR-proADM alone is not enough to diagnose AA early. The combination of low values of MR-proADM and CRP can help select children with a low risk of AA. |
|
| |||||||||||
| Sardà M. et al. (2012) [ | P, O, SC | <18 yr | pro-ADM | To determine the levels of pro-ADM in children with | Radiological imaging | The median level of pro-ADM was 1.0065 nmol/L (IQR 0.3715–7.2840) | Higher levels of pro-ADM at admission were related to a greater likelihood of complications during the hospital stay, especially pleural effusion. | ||||
| Alcoba G. et al. (2015) [ | P, O, MC | <16 yr | pro-ADM CoPEP | To assess the diagnostic accuracy of pro-ADM and CoPEP for predicting CAP complications in children. | Culture, chest X-ray | 0.72 | 0.16 nmol/L (complications) | 72.7 | 71.4 | 26.7/94.8 | Proadrenomedullin seems to be a reliable and readily available predictor for CAP complications. |
| Esposito S. et al. (2016) [ | P, O, MC | 4 mo-14 yr | sTREM-1 | To evaluate the diagnostic accuracy of biomarkers to distinguish bacterial from viral CAP and to identify severe cases of CAP. | Blood and respiratory samples, real-time PCR, | 0.58 | 0.32 nmol/L | 78.0 | 35.7 | 59.8/57.0 | MR-proADM blood levels cannot be used to differentiate bacterial from viral diseases or to identify severe cases. |
| Korkmaz M.F. et al. (2018) [ | P, O, SC | 3 mo-18 yr | pro-ADM | To investigate the value of Pro-ADM and IL-1β for severity assessment and outcome prediction in children with CAP. | Chest imaging, culture, | - | 1.75 nmol/L | 90 | 66.6 | - | Pro-ADM may offer additional risk/severity stratification in children with CAP and may be helpful in predicting the development of complications (need for PICU admission and intervention procedures). |
|
| |||||||||||
| Dötsch J. et al. (1998) [ | CC, SC | 2 w–8 yr | Urine ADM | To investigate whether UTIs are associated with increased urine ADM excretion. | Culture | ADM levels in children with UTIs were significantly higher than in controls (0.6 ± 0.41 vs. 0.15 ± 0.14 ng/μmol creatinine | Urinary tract infections | ||||
| Kalman S. et al. (2005) [ | CC, SC | 6–18 mo | Plasma and urine ADM | To determine plasma and urine ADM levels in children with APN and compare the results with a control group. | Culture, | The plasma ADM levels were lower in APN patients than in the control group ( | Urine ADM may have a role in APN. The importance of plasma ADM in the pathogenesis of acute pyelonephritis remains to be determined. | ||||
| Sharifian M. et al. (2013) [ | CC, SC | 1 mo-10 yr | Urine ADM | To evaluate the association between APN and urine ADM, as well as the effect of treatment on ADM levels. | DMSA | - | Urine ADM > 100 pg/dL (APN diagnosis) | 67.7 | 70 | 70/67.7 | This marker can be used for confirming the diagnosis and evaluating response to treatment in combination with other biomarkers. |
| Cetin N. et al. (2020) [ | CC, SC | 2–18 yr | PSP | To investigate the diagnostic values of presepsin, pro-ADM, and TREM-1 levels in children with APN and lower UTI. | Culture, | 0.83 | 63.86 pg/mL | - | - | 92.1/87.5 | Plasma pro-ADM could be a useful biomarker for the early diagnosis of acute pyelonephritis in children. |
| Peñalver R. et al. (2021) [ | P, O, SC | <16 yr | Plasma and urine MR-proADM | To study the usefulness of MR-proADM as a biomarker of acute and chronic renal parenchyma damage in fUTI. | Culture, | 0.92 | 0.66 nmol/L | 83.3 | 81.8 | - | P-MR-ProADM appears to have prognostic utility as a predictor of RS. |
|
| |||||||||||
| Demirkaya et al. (2015) [ | P, O, SC | <18 yr | ADM | To determine differences in serum ADM in febrile neutropoenia patient categories (CDI, FUO, MDI, sepsis). | Radiological imaging, cultures, clinical signs, | In the MDI group, ADM levels on day 3 were significantly higher than those in the CDI and FUO groups. | A correlation between serum adrenomedullin levels and the severity of febrile neutropoenia could not be demonstrated. Among adrenomedullin, CRP, and PCT, PCT demonstrates the highest correlation with the severity of infection. | ||||
| Kesik V. et al. (2016) [ | P, O, SC | 10 yr (1.66–16) * | ADM | To evaluate the role of ADM in predicting the prognosis for patients with FN. | Culture Risk categories, as described by Alexander et al., 2002 | 0.76 | 263.5 ng/L | 88 | 60 | 84.6/66.7 | ADM levels at admission were useful in identifying those at high risk and culture positivity in patients with solid tumours. |
| Agnello L. et al. (2020) [ | P, O, SC | 10 yr (0–17) * | PSP | To evaluate MR-proADM and PSP plasma levels and their kinetics in paediatric oncology patients with FN to assess their usefulness in the management of these patients. | Culture and clinical signs | 0.62 | . | - | - | - | MR-proADM had low diagnostic accuracy for blood culture positivity. |
| Fawsi M.M. et al. (2021) [ | P, O, SC | 1–15 yr | MR-proADM CRP | To assess the utility of MR-proADM as an early marker for sepsis in severely neutropenic patients with hematologic malignancies. | Culture, | 0.939 | 2.4 nmol/L | 91.6 | 85.1 | 83.3/92.4 | MR-proADM is a promising early marker for sepsis in severely neutropenic young patients with hematologic malignancies. |
|
| |||||||||||
| Michels M. et al. (2011) [ | CC, SC | <15 yr | MR-proADM CoPEP | To determine the relationship of MR-proADM and CoPEP to outcomes and their potential as biomarkers of plasma leakage in children with DHF and DSS. | WHO criteria, | Plasma MR-proADM concentrations were significantly higher in the DHF and DSS groups at enrolment than in the healthy controls. | MR-proADM may have a functional role in limiting endothelial hyperpermeability during DHF/DSS. MR-proADM may be a candidate biomarker to predict the development of DHF/DSS. | ||||
| Benito, J. et al. (2013) [ | P, O, MC | 1–36 mo | MR-proADM | To assess the usefulness of MR-pro-ADM and CT-pro-ET-1 in predicting BI and IBI in well-appearing infants with FWS. | PCT | 0.59 | ≥0.6 nmol/L | - | - | - | The overall performance of MR-proADM as a diagnostic marker of BI and IBI is poor. |
| Bueno-Campaña, M. et al. (2018) [ | P, O, | < 6 mo | MR-proADM | To explore the relationship between the need for respiratory support and MR-proADM. | - | Children who needed nasal cPAP or MV presented higher MR-proADM levels than the group that required just high-flow therapy or no extra support ( | MR-proADM could be a potential biomarker for the severity of acute bronchiolitis. | ||||
| Girona-Alarcón, M. (2021) [ | P, O, SC | Adults/children | MR-proADM PCT | To describe the characteristics of the disease in each specific population and to analyse the differences between adults and children. | - | MR-proADM levels were higher in children than in adults: 1.72 vs. 0.78 nmol/L ( | MR-proADM use should be studied in larger samples, since it could be helpful to pinpoint the risk of MIS-C in children infected with COVID. | ||||
The recorded results correspond to adrenomedullin results. Sensitivity, specificity and positive/negative predictive values are expressed as percentages. * Median and interquartile range. AUC: area under curve; Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; P: prospective; O: observational; MC: multicentre; PICU: paediatric intensive care unit; yr: years; MR-proADM: mid-regional pro-adrenomedullin; CT-proET-1: carboxy-terminal pro-endothelin-1; PCT: procalcitonin; CRP: C-reactive protein; PRISMIII: Pediatric Risk of Mortality III score; PIM: Pediatric Index of Mortality; SC: single centre; d: days; CC: case control; SIRS: systemic inflammatory response syndrome; ED: emergency department; AA: acute appendicitis; WBC: white blood cell count; PAS: pediatric appendicitis score; CAP: community-acquired pneumonia; pro-ADM: pro-adrenomedullin; CoPEP: copeptin; mo: months; sTREM-1: soluble triggering receptor expressed on myeloid cells 1; MR-proANP: mid-regional pro-atrial natriuretic peptide; BTS: British Thoracic Society; IL-1β: Interleukin 1β; w: weeks; UTI: urinary tract infection; ADM: adrenomedullin; APN: acute pyelonephritis; DMSA: 99mTc dimercaptosuccinic acid scintigraphy; PSP: presepsin; TREM-1: triggering receptor expressed on myeloid cells 1; ESR: erythrocyte sedimentation rate; fUTI: febrile urinary tract infection; RS: renal scarring; CDI: clinically documented infection; FUO: fever of unknown origin; MDI: microbiological documented infection; FN: febrile neutropoenia; DHF: dengue haemorrhagic fever; DSS: dengue shock syndrome; WHO: world health organization; FWS: fever without source; BI: bacterial infection; IBI: invasive bacterial infection; cPAP: continuous positive airway pressure; MV: mechanical ventilation; ARDS: acute respiratory distress syndrome; MIS-C severe multisystem inflammatory syndrome, COVID-19 related; NT-proBNP: N-terminal pro-B-type natriuretic peptide.
Adrenomedullin and cardiovascular disease.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||
| Yoshibayashi M. et al. (1999) [ | CC, SC | 0.8–18 yr | ADM | To investigate the pathophysiological significance of ADM in hypoxaemia caused by cyanotic CHD. | - | Patients with cyanotic CHD showed significantly higher concentrations of ADM and an increased uptake of adrenomedullin in the pulmonary circulation (compared to arterial-venous levels of ADM) was also detected. | ADM levels may function as a compensatory mechanism for hypoxaemia in cyanotic congenital heart disease. | ||||
| Watanabe K. et al. (2003) [ | CC, SC | 8.3 ± 7.2 yr * | ADM-m ADM-Gly | To investigate the pathophysiological role of two forms of ADM, ADM-m and ADM-Gly, in CHD. | Echocardiography and cardiac catheterisation | Plasma ADM-m and ADM-Gly were examined in cyanotic CHD and intracardiac repair with PH. | ADM levels may play beneficial roles in reducing pulmonary arterial resistance or alleviating hypoxaemia in these patients. | ||||
| Zhu X.B. et al. (2006) [ | CC, SC | ADM | To investigate the pathophysiological role of ADM in CHD. | Echocardiography and cardiac catheterisation | Plasma ADM levels are increased in congenital heart disease with high pulmonary blood flow and hypertension or with cyanosis, | Increased ADM levels may play a role in reducing the pulmonary arterial resistance and alleviating hypoxaemia in these patients. | |||||
|
| |||||||||||
| Komai H. et al. (1998) [ | P, O, SC | 2–8 mo children 6 children with cyanotic CHD 8 children with high pulmonary arterial flow due to CHD 7 adults with MV disease | ADM | To evaluate ADM in patients undergoing CPB as a marker of pulmonary vascular damage. | - | The plasma ADM level increased significantly after CPB in each group. | ADM may provide information regarding CPB-induced endothelial damage. The difference in ADM production in the high pulmonary arterial flow group may have been a consequence of the pre-existing pulmonary damage in these patients. | ||||
| Szekely L. et al. (2000) [ | P, O, SC | 1–99 mo | ADM | To study whether perioperative myocardial injury could be altered by the presence of ADM. | Troponin-I | Preoperative ADM levels in the group with little or no evidence of myocardial injury after the surgery were significantly greater than the groups with either moderate or severe injury. | Higher preoperative ADM levels are associated with lower levels of myocardial injury (as assessed by troponin-I release) during surgery for congenital heart defects. | ||||
| Takeuchi M. et al. (2001) [ | P, O, SC | 7 mo–6 yr | ADM | To elucidate the effects of ADM on fluid homeostasis during CPB. | - | ADM levels increased gradually, with a peak 60 min after CPB, and decreased 24 h after the operation. | ADM plays an important role in fluid homeostasis during CBP, in cooperation with other hormones. | ||||
| Florio P. et al. (2008) [ | P, O, SC | 126 ± 110 d * | ADM | To determine whether ADM measurement is useful for monitoring cerebral distress during CPB. | Neurological signs at physical examination using the Amiel–Tison test | 0.897 | 17.4 ng/L | 100 | 73 | - | Infants who developed abnormal neurologic sequelae had significantly higher MCA PI values and lower ADM concentrations; thus, these indicators may be useful for the early identification of infants at risk for brain damage. |
| Abella R. et al. (2012) [ | P, O, SC | 0–9 mo | ADM | To investigate whether perioperative ADM levels can predict risk of LCOS. | Clinical/laboratory findings, inotropic score, cardiac death, echocardiography | 0.842 | 27 pg/L | 100 | 64.1 | 39.1/100 | ADM might be, alone or in combination with standard parameters, a promising predictor of LCOS in infants subjected to open-heart surgery with CPB. |
| Arkader R. et al. (2013) [ | P, O, SC | 39 ± 16 mo * | C-peptide CRP | To improve our understanding of the metabolic and inflammatory factors that are involved in glucose regulation in children after CPB. | - | The ADM levels before CPB were slightly higher than normal, and increases of 323% were observed on day 1 after CPB; levels returned to baseline on day 3. | ADM may be a predictor of low insulin concentration after CPB. | ||||
| Pérez-Navero J. et al. (2017) [ | P, O, SC | 10 d–15 yr | ANP | To assess biomarkers as indicators of LCOS in children undergoing CPB. | Echocardiography (LVEF), PiCCO (CI), clinical and analytical criteria | 0.848 | 1.5 nmol/L | 88 | 66 | 50/93 | cTn-I at 2 h post-CPB and ADM at 24 h post-CPB were independent predictors of LCOS. |
| Pérez-Navero J. et al. (2018) [ | P, O, SC | 10 d–15 yr | MR-proADM cTn-I | To determine the predictive value of IS, VIS, MR-proADM, and cTn-I for LCOS in children undergoing CPB. | Echocardiography (LVEF), PiCCO (CI), clinical and analytical criteria | 0.81 | Prediction model 1 (age, CPB > 120 min, VIS) | 55.5 | 92.9 | 74.7/79.59 | The VIS score at 2 h post-CPB was identified as an independent early predictor of LCOS. This predictive value was not significantly increased when associated with cardiac biomarkers for LCOS. |
| Bobillo-Pérez S. et al. (2019) [ | P, O, SC | 1 mo–16 yr | PCT | To assess the usefulness of PCT, pro-ADM, and pro-ANP as predictors of need for MV, inotropic support, and bacterial infection in patients after CPB. | - | 0.721 | 1.22 nmol/L immediately after CPB (predicting MV need) | 69.5 | 87 | 80.2/78.9 | Pro-ADM and pro-ANP are good predictors of need for MV and LOS after CPB. Procalcitonin is useful for predicting bacterial infection. |
| Bobillo-Pérez S. et al. (2020) [ | P, O, SC | 2.1 yr (0.6–6.6) ** | MRpro-ADM pro-ANP | To evaluate the utility of pro-ANP and pro-ADM levels prior to CPB for predicting the need for intensive post-CPB support. | - | 0.724 | pro-ADM for predicting increased respiratory support | - | - | - | In the multivariable analysis, pro-ADM wasn’t identified as an independent predictor for increased need for respiratory or inotropic support. |
|
| |||||||||||
| Hiramatsu T. et al. (1999) [ | CC, SC | 1–14 yr | ET-1 | To examine the time course of ET-1 and ADM and to explore their influence on pulmonary vascular tone. | Cardiac catheterisation | ET-1 and ADM increased after CPB in both groups. | An imbalance between increased ET-1 and decreased ADM after CPB during the Fontan procedure induces vasoconstriction. | ||||
| Watanabe K. et al. (2007) [ | CC, SC | 1.4–22.6 yr | ADM-m ADM-Gly ADM-T | To investigate the significance of molecular forms of ADM in patients after the Fontan procedure. | Follow-up cardiac catheterisation (period between the Fontan procedure and the examination was 5.8 ± 4.9 yr) | Fontan patients had significantly higher venous concentrations of ADM-T, ADM-Gly, and ADM-m than controls. | ADM may be involved in the regulation of pulmonary arterial tone following Fontan surgery. | ||||
| Kaiser R. et al. (2014) [ | CC, SC | 4–36 yr | MR-proADM | To assess the utility of MR-proADM as a predictor of Fontan procedure failure. | Echocardiography, abdominal and pleural ultrasound, | 0.985 | >0.520 nmol/L | 100 | 93.9 | 57.1/100 | Serial measurements of MR-proADM levels may help identify patients at risk for a failing Fontan circulation, especially when these exceed 0.520 nmol/L. |
|
| |||||||||||
| Randa Abdel Kader M. et al. (2007) [ | CC, SC | ADM | To evaluate ADM and ANP in patients with CHF and investigate their relationship with haemodynamic variables. | NYHA functional classification, | Plasma levels of ADM and ANP increased in adult and paediatric patients with CHF, irrespective of the cause. | ADM and ANP may be used to identify high-risk subjects for HF during more invasive procedures. | |||||
| Hauser J. et al. (2016) [ | CC, MC | 0–24 yr | MR-proANP sST2 | To assess the diagnostic utility of four novel biomarkers in paediatric HF. | Presence of HF symptoms, abnormal systolic ventricular function via MRI or echocardiography | ROC analysis showed poor accuracy for MR-proADM (AUC 0.61, 95% CI 0.48–0.69, | MR-proADM shows unsatisfactory diagnostic power. | ||||
|
| |||||||||||
| Kılınc M. et al. (2003) [ | CC, SC | 5 mo–14 yr | Plasma and urine ADM and NO | To determine plasma and urine AM and NO in children | Echocardiography, signs and symptoms of DCM | Plasma and urine ADM levels were significantly lower than in the healthy controls. | Low ADM levels may be a bad prognostic factor for children with DCM in advanced stages. | ||||
|
| |||||||||||
| Zhang F. et al. (2012) [ | CC, SC | 7–14 yr | MR-proADM | To explore the predictive value of MR-proADM in assessing the therapeutic efficacy of midodrine hydrochloride for children with POTS. | Symptom scoring and | 0.879 | 61.5 pg/mL | 100 | 71.6 | -/- | MR-proADM can help guide midodrine hydrochloride therapy in the management of POTS in children, identifying those who will have a good response to the drug. |
| Li H. et al. (2015) [ | P, O, SC | 14.5 ± 4.5 yr * | MR-proADM | To explore the predictive value of baseline plasma MR-proADM for the long-term survival of children with POTS treated with midodrine hydrochloride. | Orthostatic intolerance symptom score and symptom-free survival | At the 60-month follow-up, patients with baseline MR-proADM of >61.5 ng/L had a significantly lower symptom score. | The baseline plasma MR-proADM level is valuable for predicting the long-term survival of children with POTS treated with midodrine hydrochloride. | ||||
|
| |||||||||||
| Wu R.Z. et al. (2010) [ | CC, SC | ADM | To observe changes in ADM and BNP before and after transcatheter closure in children with PDA. | - | Before transcatheter closure, concentrations of plasma ADM were significantly higher in patients with PDA compared to the control group. | Plasma ADM levels decreased significantly after transcatheter closure in children with PDA. | |||||
The recorded results correspond to adrenomedullin. Sensitivity, specificity, and positive/negative predictive values are expressed as percentages.* Mean and standard deviation. ** Median and interquartile range. AUC: area under curve; Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; CC: case control; SC: single centre; yr: years; CHD: congenital heart disease; KD: Kawasaki disease; ADM: adrenomedullin; ADM-m: mature adrenomedullin; ADM-Gly: glycine-extended adrenomedullin; PH: pulmonary hypertension; SAsat: systemic arterial oxygen saturation; Rp: pulmonary arterial resistance; P: prospective; O: observational; mo: months; MV: mitral valve; CPB: cardiopulmonary bypass; mPAP: mean pulmonary arterial pressure; VP: vasopressin; ANP: atrial natriuretic peptide; BNP: brain natriuretic peptide; ALD: aldosterone; d: days; MCA PI: middle cerebral artery pulsatility index; LCOS: low cardiac output syndrome; MP: methylprednisolone; IL-6: interleukin 6; CoPEP: copeptin; MR-proADM: mid-regional pro-adrenomedullin; cTn-I: cardiac troponin I; LVEF: left ventricle ejection fraction; CI: cardiac index; IS: inotropic score; VIS: vasoactive-inotropic score; PCT: procalcitonin; pro-ANP: pro atrial natriuretic peptide; MV: mechanical ventilation; LOS: length of stay; CVP: central venous pressure; ET-1: endothelin-1; ADM-T: total adrenomedullin; CHF: congestive heart failure; ANP: atrial natriuretic peptide; NYHA: New York Heart Association; FS: fractional shortening; HF: heart failure; MC: multicentre; sST2: soluble ST2; GDF-15: growth differentiation factor-15; NT-proBNP: N-terminal pro-B natriuretic peptide; MRI: magnetic resonance imaging; DCM: dilated cardiomyopathy: LV: left ventricular; NO: nitric oxide; EF: ejection fraction; POTS: postural orthostatic tachycardia syndrome; HUT: head-up test; HUTT: head-up tilt test; PDA: patent ductus arteriosus; BNP: B-type natriuretic peptide.
Adrenomedullin and pulmonary hypertension.
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yoshibayashi M. et al. (1997) [ | CC, SC | 9 mo–19 yr | ADM-LI | To elucidate the pathophysiological significance of ADM in PH. | Cardiac catheterisation | Plasma AM-LI concentrations in the C-PH group and the P-PH group were significantly higher than in the no PH group. | ADM may be involved in the cardiovascular regulation or homeostasis of pulmonary circulation in pulmonary hypertension. | ||||
| Vijay P. et al. (1998) [ | P, O, SC | 9 yr | ADM | To examine the influence of these biomarkers in the development of postoperative PH. | Cardiac catheterisation or echocardiography | ADM levels were significantly higher in LF groups compared to HF groups ( | ADM appears to affect baseline vascular tone in patients with intact endothelial function. | ||||
| Nakayama, T. (2001) [ | P, O, SC | 12 ± 4 yr * | ANP | To investigate whether plasma levels of ADM are useful for assessing the severity of P-PH. | NYHA classification, pulmonary haemodynamics, and 6 min. walk test | ADM significantly decreased at 1 month and at 3 months. | ADM was valuable for evaluating both cardiac performance and pulmonary haemodynamics after long-term treatment with PGI2 in patients with primary pulmonary hypertension. | ||||
| Lu H. et al. (2003) [ | CC, SC | 2 mo–16 yr | ADM | To investigate their role in CHD with PH. | - | Plasma ADM levels were significantly higher in patients with CHD than in the control group ( | ADM may play an important role in the development of PH in patients with CHD. ADM may be involved in the defence mechanism against further increases in pulmonary arterial pressure. | ||||
| Wang, T. (2005) [ | P, O, SC | ADM | To evaluate the effects and clinical significance of ADM and UII as regards PH. | - | As pulmonary hypertension increases in severity, the plasma levels of ADM increase. | Measuring the levels of ADM may be a reliable method to monitor changes in pulmonary pressure and the worsening of pulmonary hypertension. | |||||
The recorded results correspond to adrenomedullin. Sensitivity, specificity, and positive/negative predictive values are expressed as percentages. * Mean and standard deviation. AUC: area under curve; Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; CC: case–control; SC: single centre; mo: months; yr: years; C-PH: cardiac pulmonary hypertension; P-PH: primary pulmonary hypertension; PH: pulmonary hypertension; ADM-LI: plasma adrenomedullin-like immunoreactivity; ADM: adrenomedullin; PA: pulmonary artery; PV: pulmonary vein; P: prospective; O: observational; CHD: congenital heart disease; ET-1: endothelin-1; NO2: nitrites; NO3: nitrates; LF: low pulmonary flow; HF: high pulmonary flow; CPB: cardiopulmonary bypass; ANP: atrial natriuretic peptide; BNP: brain natriuretic peptide; NYHA: New York Heart Association; PGI2: prostaglandin I2; mo: months; NO: nitric oxide; PASP: pulmonary artery systolic pressure; UII: urotensin-II.
Adrenomedullin in nephro-urological disease.
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Balat et al. (2000) [ | CC, SC | 6 mo–10 yr | Urine and plasma total nitrite and ADM | To verify whether NO and ADM play a role in the reduced vascular response seen in Bartter syndrome. | - | Plasma ADM levels were higher in those with Bartter syndrome than in the other groups ( | The increased production of ADM may have a role in the reduced vascular response seen in Bartter syndrome. | ||||
| Balat A. et al. (2000) [ | CC, SC | 2–10 yr | Urinary and plasma total nitrite and ADM | To study plasma and urine ADM and NO concentrations in children w/MCNS during relapse and remission. | Clinical criteria | Plasma ADM concentrations during relapse were significantly lower than in remission and controls, and urine ADM levels were significantly higher in relapse than in remission and controls. | The important changes in plasma and urine ADM levels in relapse suggested that these changes may be compensatory when the body experiences severe proteinuria. | ||||
| Balat A. et al. (2002) [ | CC, SC | 8.05 ± 1.61 yr * | Urinary and plasma total nitrite and ADM | To investigate if plasma and urine ADM and nitrite levels are altered in children with PNE. | Clinical criteria | Plasma and urine ADM levels were significantly lower in children with PNE than in controls ( | Decreased ADM levels may be a compensatory response when there is abnormal electrolyte and water excretion. | ||||
| Balat A. et al. (2003) [ | CC, SC | 6.43 ± 2.62 yr | Tissue levels of NO and ADM | To determine the tissue levels of NO and ADM in children with DI and compare them with children with normal bladder activity. | Urodynamic testing | ADM levels measured via bladder biopsy (pmol/g tissue) were increased in children with DI ( | Increased ADM appears to be compensatory for decreased NO production in the smooth muscle of the bladder in DI patients. | ||||
| Kalman S. et al. (2005) [ | CC, SC | 1–13 yr | Plasma and urine ADM | To determine plasma and urine ADM levels in children with RPS and VUR. | Cystoureterography | Plasma ADM levels were not significantly higher in the control group than in the rest of the groups ( | Urine ADM can be a prognostic factor in the long-term follow-up of paediatric cases with VUR. | ||||
The recorded results correspond to adrenomedullin. Sensitivity, specificity, and positive/negative predictive values are expressed as percentages. * Mean and standard deviation. AUC: area under curve; Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; CC: case–control; SC: single centre; yr: years; ADM: adrenomedullin; DMSA: 99mTc dimercaptosuccinic acid scintigraphy; mo: months; NO: nitric oxide; MCNS: minimal change nephrotic syndrome; PNE: primary nocturnal enuresis; DI: detrusor instability; RPS: renal parenchymal scar; VUR: vesicoureteral reflux.
Adrenomedullin and endocrine disease.
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Del Ry S. et al. (2016) [ | CC, SC | 12.5 ± 0.4 yr * | MR-proADM | To assess plasma MR-proADM levels in obese adolescents compared to normal-weight subjects. | National BMI reference data specific for age and sex | Plasma MR-proADM levels were significantly higher in obese adolescents than in normal-weight ones ( | Obese adolescents have higher circulating levels of MR-proADM compared to those of normal weight, suggesting its important involvement in obese patients. | ||||
| Metwalley K.A. et al. (2018) [ | CC, SC | 9.76 ± 2.21 yr * | ADM | To determine the plasma levels of ADM in obese children and their relationship to LV function. | Echocardiography | - | 52 pg/mL (predicting LV hypertrophy) | 94.3 | 92.5 | - | Measuring plasma ADM levels in obese children may help to identify those at high risk of developing LV hypertrophy and dysfunction. |
| El-Habashy S. et al. (2010) [ | CC, SC | 13.9 ± 3.2 yr * | ADM | To assess ADM levels in children and adolescents with T1DM and their correlation with diabetic MVC. | Indirect ophthalmoscope examination of the fundus | ADM levels were significantly increased in patients with and without MVC compared to the control group, with higher levels in those with MVC. | ADM may have a role in the diabetic vasculopathy of children and adolescents with T1DM. | ||||
| Semeran K. et al. (2013) [ | CC, SC | 8–18 yr | HbA1c | To assess the use of biomarkers in patients with T1DM with no visible lesions for predicting retinal dysfunction. | S-cone | A statistically significant finding was that the ADM level in the diabetes group was lower than in the control group ( | The changes observed in the ADM levels support its possible involvement in the microvascular complications of diabetes. Different-than-expected study results as regards ADM concentration indicate that further studies are needed. | ||||
The recorded results correspond to adrenomedullin. Sensitivity, specificity, and positive/negative predictive values are expressed as percentages. * Mean and standard deviation. AUC: area under curve; Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; CC: case–control; SC: single centre; yr: years; MR-proADM: mid-regional pro-adrenomedullin; BMI: body mass index; ADM: adrenomedullin; LV: left ventricle; T1DM: type 1 diabetes mellitus; ADM: adrenomedullin; MVC: microvascular complications; IL-17: interleukin-17; VEGF: vascular endothelial growth factor.
Adrenomedullin and rheumatic diseases.
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nishida K. et al. (2001) [ | P, O, SC | 0.4–2.6 yr | ADM | To test ADM as an early detection biomarker of coronary artery vasculitis in KD. | Echocardiography | ADM levels were markedly elevated before treatment, especially in patients with coronary artery dilation. | ADM may be useful to monitor Kawasaki disease patients during its acute phase and may help to diagnose coronary artery involvement. | ||||
| Islek I. et al. (2003) [ | CC, SC | 11.4 ± 3.1 * | Plasma and urine NO and ADM | To measure ADM and NO levels in children with HSP. | Diagnostic criteria | Plasma and urine ADM levels were significantly higher in the acute phase of HSP than in the controls. | ADM may have a role in the immune-inflammatory process of HSP, especially in the active stage. | ||||
| Balat A. et al. (2005) [ | CC, SC | 7–14 yr | Plasma and urine NO and AM | To investigate whether an association between levels of ADM/NO and ARF exists. | Diagnostic criteria | Plasma and urine ADM levels were significantly higher in children with ARF, irrespective of whether they were in the acute or convalescent phases. | ADM may play a role in the immune-inflammatory process of ARF. However, increased levels may also be the result of inflammatory injury in ARF. | ||||
| Balat A. et al. (2006) [ | CC, SC | 3–16 yr | Plasma and urine NO and ADM | To determine the levels of ADM and NO in children w/FMF and compare with the healthy controls. | Diagnostic criteria | Plasma and urine levels were significantly higher in FMF patients than in controls. | ADM may have a role in the immuno-inflammatory process of FMF, although whether these act to promote or protect against further inflammatory injury is not clear. | ||||
| Kalman S. et al. (2012) [ | CC, SC | 9.2 ± 4.7 yr * | Urine and plasma ADM | To compare plasma and urine ADM levels of FMF patients who exhibit M694V homozygosity and patients with other genotypes. | - | Plasma ADM levels were higher in FMF patients w/homozygous M694V than other patients (heterozygous M694V and other mutations). | Although the results are favourable, more studies are needed to demonstrate the association between homozygous M694V mutation and ADM levels. | ||||
| Polat A. (2015) [ | CT, SC | 7.8 ± 2 yr | ADM | To investigate ADM as a marker for inflammation in paediatric patients with FMF who are using colchicine at different doses. | ESR and CRP levels | ADM levels were similar in all visits ( | No alterations in ADM levels were demonstrated at any visits, which may suggest the continuation of subclinical inflammation in these patients. | ||||
The recorded results correspond to adrenomedullin. Sensitivity, specificity, and positive/negative predictive values are expressed as percentages. * Mean and standard deviation. AUC: area under curve; Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; P: prospective; O: observational; SC: single centre; yr: years: KD: Kawasaki disease; ADM: adrenomedullin; CC: case–control; HSP: Henoch-Schönlein purpura; NO: nitric oxide; ARF: acute rheumatic fever; ESR: erythrocyte sedimentation rate; EF: ejection fraction; FMF: Familial Mediterranean Fever; CT: clinical trial; CRP: C-reactive protein.
Other articles published on adrenomedullin in children.
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Özgür B.G. et al. (2017) [ | CC, SC | 9.2 ± 2.8 yr * | ADM | To compare plasma ADM and NO levels of newly diagnosed, treatment-naive patients with ADHD and healthy children. | K-SADS-PL-T schedule | There were no statistically significant differences in NO and ADM levels, neither between the groups nor ADHD subtypes. | The role of ADM in the pathophysiology of ADHD could not be demonstrated. | ||||
| Zoroglu S.S. et al. (2003) [ | CC, SC | 2–12 yr | ADM | To assess the role of NO and ADM in autism. | DSM-IV diagnostic criteria | The mean values of plasma total nitrite and ADM levels in the autistic group were significantly higher than control values. | ADM may have a pathophysiological role in autism; this subject requires much further research. | ||||
| Kucukosmanoglu E. et al. (2012) [ | CC, SC | 5–15 yr | ADM | To determine changes in ADM levels during an acute asthma attack and its association with allergen sensitivity. | GINA classification, prick tests | No significant differences were found in ADM levels between the controls and patients in either the acute attack or remission period. | ADM may play a role in children with atopic dermatitis and may also have a role in the immuno-inflammatory process of asthma. | ||||
| Piccin A. et al. (2015) [ | CC, SC | MP | To investigate the relationship between MP, PC, PS, NO, ET-1, and pro-ADM in paediatric patients with SCA. | - | Pro-ADM levels were elevated in acute chest syndrome versus steady state and controls. | During an acute chest crisis, ADM and ET-1 were elevated, suggesting a role for therapy inhibiting ET-1. | |||||
| Robertson C.L. et al. (2001) [ | CC, SC | 1.5 mo–11 yr | CSF ADM | To investigate whether post- traumatic CSF ADM concentration was associated with relevant clinical variables (CBF). | Glasgow scale | ADM concentration was markedly increased in the CSF of infants and children after severe TBI versus controls. | ADM may participate in the regulation of CBF after severe TBI. | ||||
The recorded results correspond to adrenomedullin. Sensitivity, specificity, and positive/negative predictive values are expressed as percentages. * Mean and standard deviation. AUC: area under curve; Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; CC: case control; SC: single centre; yr: years; ERG: electroretinogram; ADHD: attention deficit hyperactivity disorder; NO: nitric oxide; SCA: sickle cell anaemia; MP: circulating microparticles; PC: protein C; PS: free protein S; pro-ADM: proadrenomedullin; ET-1: endothelin-1; mo: months; TBI: traumatic brain injury; CSF: cerebrospinal fluid; CBF: cerebral blood flow; CT: computed tomography.
Figure 1Flow diagram.
Figure 2Summary of the quality of the studies included in this review. * means that in the question “if a threshold was used, as it prespecified?”.